ClinicalTrials.gg
CompletedNCT01970072Updated Jan 31, 2018

A Phase Ⅰa Study of Remimazolam Tosylate in Healthy Volunteers

A Phase 1 interventional study of Remimazolam Tosylate and Midazolam in Healthy, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-31.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate and compare the Pharmacokinetics/Pharmacodynamics and safety of Remimazolam Tosylate with midazolam in healthy volunteers

02

Conditions studied

  • Healthy

Keywords

  • Remimazolam Tosylate
  • Phase Ⅰ study
  • Health
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or females
  • Weight range 50 to 100 kg inclusive
  • (BMI) 18 to 26 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Has a known sensitivity to benzodiazepines, flumazenil, or anesthetic agents, or a medical condition such that these agents are
  • With evidence of uncontrolled renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction, in the opinion of the investigator or medical monitor
  • Has known or suspected history of alcoholism or drug abuse or misuse within 6 months of Screening or evidence of tolerance or physical dependence before dosing with study drug
  • With a history of laboratory results that show the presence of surface antigen (HBs Ag), antibody (HCV Ab), or (HIV)
  • Pregnant,lactating
  • Mallampati score ≥3
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    1.Remimazolam Tosylate

    Single IV bolus of Remimazolam Tosylate over 1 minute at 0.01 mg/kg body weight

    Drug: Remimazolam Tosylate

  • Experimental
    2.Remimazolam Tosylate

    Single IV bolus of Remimazolam Tosylate over 1 minute at 0.02 mg/kg body weight

    Drug: Remimazolam Tosylate

  • Experimental
    3.Remimazolam Tosylate

    Single IV bolus of Remimazolam Tosylate over 1 minute at 0.05 mg/kg body weight

    Drug: Remimazolam Tosylate

  • Experimental
    4.Remimazolam Tosylate

    Single IV bolus of Remimazolam Tosylate over 1 minute at 0.075 mg/kg body weight

    Drug: Remimazolam Tosylate

  • Experimental
    5.Remimazolam Tosylate

    Single IV bolus of Remimazolam Tosylate over 1 minute at 0.1 mg/kg body weight

    Drug: Remimazolam Tosylate

  • Experimental
    6.Remimazolam Tosylate

    Single IV bolus of Remimazolam Tosylate over 1 minute at 0.15 mg/kg body weight

    Drug: Remimazolam Tosylate

  • Experimental
    7.Remimazolam Tosylate

    Single IV bolus of Remimazolam Tosylate over 1 minute at 0.2 mg/kg body weight

    Drug: Remimazolam Tosylate

  • Experimental
    8.Remimazolam Tosylate

    Single IV bolus of Remimazolam Tosylate over 1 minute at 0.25 mg/kg body weight

    Drug: Remimazolam Tosylate

  • Experimental
    9.Remimazolam Tosylate

    Single IV bolus of Remimazolam Tosylate over 1 minute at 0.3mg/kg body weight

    Drug: Remimazolam Tosylate

  • Experimental
    10.Remimazolam Tosylate

    Single IV bolus of Remimazolam Tosylate over 1 minute at 0.35 mg/kg body weight

    Drug: Remimazolam Tosylate

  • Active comparator
    11.Midazolam

    Single IV bolus of Midazolam over 1 minute at 0.075 mg/kg body weight

    Drug: Midazolam

Interventions

06

What researchers measure

Primary outcomes

  1. To study the Pharmacokinetics of Remimazolam Tosylate by assessment of drug concentration through blood sample analysis

    Time frame: Pre-dose to 8 hours post-dosee

  2. Bispectral index (BIS) and Modified Observer's Assessment of Alertness/Sedation(MOAA/S) score assessments

    Time frame: Pre-dose to 2 hours post-dose

  3. Adverse event;Vital sign;Physical examination;Laboratory examination;ECG;The nervous system function test

    Time frame: Pre-dose to 24 hours post-dose

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, 100032, China
08

References and documents

Publications

  • Chen X, Sang N, Song K, Zhong W, Wang H, Jiang J, Huang Y, Hu P. Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote. Clin Ther. 2020 Apr;42(4):614-624. doi: 10.1016/j.clinthera.2020.02.006. Epub 2020 Mar 13. PubMed 32178858 ↗
  • Zhou Y, Hu P, Huang Y, Nuoer S, Song K, Wang H, Wen J, Jiang J, Chen X. Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects. Front Pharmacol. 2018 Nov 19;9:1316. doi: 10.3389/fphar.2018.01316. eCollection 2018. Erratum In: Front Pharmacol. 2019 Mar 19;10:251. doi: 10.3389/fphar.2019.00251. PubMed 30510509 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2013 to primary completion in Jun 2014, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2013
First posted
Oct 25, 2013
StartActual
Oct 14, 2013
Primary completionActual
Jun 20, 2014
CompletionActual
Jun 20, 2014
Last update
Jan 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01970072
Responsible party
Sponsor
First posted
Oct 25, 2013
Start date
Oct 14, 2013
Primary completion
Jun 20, 2014
Completion
Jun 20, 2014
Last update
Jan 31, 2018

Study contacts

Bei Hu, Professor
principal investigator · Peiking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam tosylate

Start the discussion